ArticleJournal of cell science2010
Roadblocks en route to the clinical application of induced pluripotent stem cells.
Article in Journal of cell science, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Frequency-induced morphology alterations in microconfined biological cells.Medical & biological engineering & computing · 2019Article
- Non-viral, Tumor-free Induction of Transient Cell Reprogramming in Mouse Skeletal Muscle to Enhance Tissue Regeneration.Molecular therapy : the journal of the American Society of Gene Therapy · 2019Article
- Nanog induces suppression of senescence through downregulation of p27KIP1 expression.Journal of cell science · 2016Article
- Current status of pluripotent stem cells: moving the first therapies to the clinic.Nature reviews. Drug discovery · 2015Review
- High-Throughput Assessment of Cellular Mechanical Properties.Annual review of biomedical engineering · 2015Review
- Modeling AEC-New approaches to study rare genetic disorders.American journal of medical genetics. Part A · 2014Review
- Human pluripotent stem cell-derived retinal pigmented epithelium in retinal treatment: from bench to bedside.Molecular neurobiology · 2014Review
- Directing human induced pluripotent stem cells into a neurosensory lineage for auditory neuron replacement.BioResearch open access · 2014Article
- Stem cells' guided gene therapy of cancer: New frontier in personalized and targeted therapy.Journal of cancer research & therapy · 2014Article
- From "ES-like" cells to induced pluripotent stem cells: a historical perspective in domestic animals.Theriogenology · 2014Review
- Suicide Gene Therapy for Cancer - Current Strategies.Journal of genetic syndromes & gene therapy · 2013Article
- Safeguarding Stem Cell-Based Regenerative Therapy against Iatrogenic Cancerogenesis: Transgenic Expression ofJournal of stem cell research & therapy · 2013Article
- Concise review: carbon nanotechnology: perspectives in stem cell research.Stem cells translational medicine · 2013Review
- Article
- From skin biopsy to neurons through a pluripotent intermediate under Good Manufacturing Practice protocols.Stem cells translational medicine · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Since the first studies of human embryonic stem cells (hESCs) and, more recently, human induced pluripotent stem cells (hiPSCs), the stem-cell field has been abuzz with the promise that these pluripotent populations will one day be a powerful therapeutic tool. Although it has been proposed that hiPSCs will supersede hESCs with respect to their research and/or clinical potential because of the ease of their derivation and the ability to create immunologically matched iPSCs for each individual patient, recent evidence suggests that iPSCs in fact have several underappreciated characteristics that might mean they are less suitable for clinical application. Continuing research is revealing the similarities, differences and deficiencies of various pluripotent stem-cell populations, and suggests that many years will pass before the clinical utility of hESCs and hiPSCs is realized. There are a plethora of ethical, logistical and technical roadblocks on the route to the clinical application of pluripotent stem cells, particularly of iPSCs. In this Essay, we discuss what we believe are important issues that should be considered when attempting to bring hiPSC-based technology to the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.